MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

Search

Elanco Animal Health Inc

Cerrado

SectorSanidad

22.75 0.62

Resumen

Variación precio

24h

Actual

Mínimo

22.53

Máximo

22.83

Métricas clave

By Trading Economics

Ingresos

-45M

-34M

Ventas

-104M

1.1B

P/B

Media del Sector

318.571

78.892

Margen de beneficios

-2.99

Empleados

9,000

EBITDA

-86M

178M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+12.21% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-272M

11B

Apertura anterior

22.13

Cierre anterior

22.75

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Elanco Animal Health Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 may 2025, 11:29 UTC

Adquisiciones, fusiones, absorciones

Elanco Sells Non-Core Asset to Blackstone for $295 Million

5 may 2025, 11:14 UTC

Adquisiciones, fusiones, absorciones

Elanco Sells Non-Core Asset to Blackstone for $295 Mln

5 may 2025, 10:50 UTC

Adquisiciones, fusiones, absorciones

Elanco Animal Health: Monetization of This Non-Core Asset Will Be Used to Accelerate Debt Reduction >ELAN

5 may 2025, 10:49 UTC

Adquisiciones, fusiones, absorciones

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone for $295M

Comparación entre iguales

Cambio de precio

Elanco Animal Health Inc previsión

Precio Objetivo

By TipRanks

12.21% repunte

Estimación a 12 Meses

Media 25.36 USD  12.21%

Máximo 30 USD

Mínimo 22 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Elanco Animal Health Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

10

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.77 / N/ASoporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Elanco Animal Health Inc

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.